Xios Therapeutics

Xios Therapeutics was a private biotechnology company focused on small-molecule immuno-oncology drug discovery. The company aimed to develop therapies that prevent tumors from evading the immune system, with work spanning immuno-oncology pathways and onco-metabolite biology. Xios also built a targeted protein degradation capability using proteolysis-targeting chimera approaches in collaboration with X-Chem, combining DNA-encoded library screening with rational drug design. Publicly available information suggests the company remained at the preclinical stage and did not advance disclosed assets into clinical development before becoming inactive/closed.